Xcytrin® (motexafin gadolinium) Injection may improve stereotactic radiosurgery treatment-planning by enhancing magnetic resonance imaging (MRI) and better defining the treatment field in patients with brain metastases from solid tumors.
Such were the preliminary results of Pharmacyclics, Inc. (Nasdaq: PCYC)’s open-label multi-center Phase 2 clinical trial on Xcytrin® (motexafin gadolinium) Injection.
This novel drug enables physicians to identify occult brain metastases that are amenable to stereotactic radiosurgery and that were missed with standard MRI contrast agents.
According to John Suh, M.D., Department Chair of Radiation Oncology at the Cleveland Clinic, and presenter of the Phase 2 results:
"These data demonstrate that Xcytrin can be used in combination with radiosurgery and whole brain radiation therapy (WBRT) for patients with brain metastases.
Our results showed that, in one-fifth of the patients enrolled in this trial, Xcytrin- based treatment planning for stereotactic radiosurgery identified occult brain metastases that are amenable to radiosurgery and were missed with standard MRI procedures."
The findings entitled: "Motexafin Gadolinium-Based Treatment Planning MRI Identifies Occult Brain Metastases Amenable to Stereotactic Radiosurgery: Results of a Phase II trial of Motexafin Gadolinium and Whole Brain Radiotherapy with Stereotactic Radiosurgery" were presented at the recent 48th American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in Philadelphia, PA.
Find more details from the press release.
Comment Preview